Allison Quick

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Background: Despite prevalent use of SEER-Medicare data to study uterine cancer treatment patterns and survival, concordance between SEER and Medicare claims has not been a focus of prior research. We assessed agreement between SEER and Medicare claims, predictors of disagreement between sources, and associations between treatment (identified in SEER- vs. Medicare) and survival. Methods: Patients diagnosed with uterine cancer between 2000 and 2019 were identified using the SEER-Medicare linked database. We calculated kappa statistics to assess agreement between the two data sources for receipt of hysterectomy with or without bilateral salpingo-oophorectomy (BSO), hysterectomy with BSO, lymphadenectomy, external beam radiotherapy (EBRT), vaginal brachytherapy (VBT), and chemotherapy. For each treatment type, we examined temporal trends in the kappa and used multivariable-adjusted logistic regression to examine predictors of disagreement. Treatment hazard ratios in Cox proportional hazards regression models using treatment information from SEER vs. Medicare were compared. Results: For each treatment, we excluded patients with unknown SEER information, resulting in variable sample sizes. Agreement was lowest for hysterectomy with BSO (kappa=0.71) and highest for lymphadenectomy and chemotherapy (kappas=0.85). Temporal variation was evident, with lymphadenectomy, EBRT, and VBT agreement dropping in recent years. Black race, younger age at diagnosis, high-risk histology, and advanced stage were associated with higher disagreement odds for certain treatments. Associations between treatment identified in SEER vs. Medicare and survival outcomes were similar. Conclusions: Treatment agreement between SEER and Medicare was high. Impact: Our results support use of both data sources for uterine cancer treatment-survival analyses.

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2022

Year:

2020

Year:

2020

Collaborators (6)

Tasleem Padamsee

Associate Professor

Ohio State University

UNITED STATES
View details

Scott R. Silva

University of Louisville

UNITED STATES
View details

Magdalena Stankiewicz

MD PhD

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Jennifer Sinnott

Associate Professor

Ohio State University

UNITED STATES
View details

Macarius M. Donneyong

Associate Professor

Ohio State University

UNITED STATES
View details

Anupam Rishi

Assistant Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details